BR112014004859A2 - preparação e composições de enxofre zerovalente altamente biodisponíveis e usos das mesmas - Google Patents
preparação e composições de enxofre zerovalente altamente biodisponíveis e usos das mesmasInfo
- Publication number
- BR112014004859A2 BR112014004859A2 BR112014004859A BR112014004859A BR112014004859A2 BR 112014004859 A2 BR112014004859 A2 BR 112014004859A2 BR 112014004859 A BR112014004859 A BR 112014004859A BR 112014004859 A BR112014004859 A BR 112014004859A BR 112014004859 A2 BR112014004859 A2 BR 112014004859A2
- Authority
- BR
- Brazil
- Prior art keywords
- sulfur
- compositions
- rich compositions
- highly bioavailable
- rich
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
Abstract
preparation and compositions of highly bioavailable zerovalent sulfur and uses thereof abstract the present invention features sulfur-rich compositions and preparations thereof that are safe and effective as hydrogen sulfide prodrugs of high bioavailability. the invention also includes methods of treating pathological conditions associated with oxidative stress using sulfur-rich compositions. the invention further includes sulfur-rich compositions as antidotes and medical food for preserving and promoting general health. tradução do resumo resumo patente de invenção: "preparação e composições de enxo-fre zerovalente altamente biodisponíveis e usos das mesmas". a presente invenção descreve composições ricas em enxofre e preparações das mesmas que são seguras e eficientes como pró-fármacos de sulfeto de hidrogênio de alta biodisponibilidade. a invenção também inclui processos de tratamento de estados de saúde patológicos associados com o estresse oxidativo utilizando composições ricas em enxofre. a invenção inclui ainda composições ricas em enxofre como antídotos e alimentação medicinal para preservar e promover a saúde geral.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161534585P | 2011-09-14 | 2011-09-14 | |
PCT/US2012/055205 WO2013040240A1 (en) | 2011-09-14 | 2012-09-13 | Preparation and compositions of highly bioavailable zerovalent sulfur and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112014004859A2 true BR112014004859A2 (pt) | 2017-06-13 |
Family
ID=47830038
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014005144-5A BR112014005144B1 (pt) | 2011-09-14 | 2012-09-13 | composições de enxofre com valência zero altamente biodisponíveis |
BR122020020392-7A BR122020020392B1 (pt) | 2011-09-14 | 2012-09-13 | Método de preparação de composições de enxofre com valência zero altamente biodisponíveis |
BR112014004859A BR112014004859A2 (pt) | 2011-09-14 | 2012-09-13 | preparação e composições de enxofre zerovalente altamente biodisponíveis e usos das mesmas |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014005144-5A BR112014005144B1 (pt) | 2011-09-14 | 2012-09-13 | composições de enxofre com valência zero altamente biodisponíveis |
BR122020020392-7A BR122020020392B1 (pt) | 2011-09-14 | 2012-09-13 | Método de preparação de composições de enxofre com valência zero altamente biodisponíveis |
Country Status (11)
Country | Link |
---|---|
US (3) | US20150064286A1 (pt) |
EP (2) | EP2756757B1 (pt) |
JP (2) | JP5992525B2 (pt) |
CN (2) | CN104080334A (pt) |
AU (3) | AU2012308501A1 (pt) |
BR (3) | BR112014005144B1 (pt) |
CA (2) | CA2847589C (pt) |
ES (1) | ES2739628T3 (pt) |
HK (2) | HK1200277A1 (pt) |
MX (2) | MX2014003288A (pt) |
WO (2) | WO2013055199A1 (pt) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8541396B2 (en) | 2009-04-24 | 2013-09-24 | National University Of Singapore | Morpholin-4-ium 4 methoxyphenyl (morpholino) phosphinodithioate (GYY4137) as a novel vasodilator agent |
US10920020B2 (en) | 2011-08-11 | 2021-02-16 | Arizona Board Of Regents On Behalf Of The University Of Arizona | 3D-printing of ultra-high refractive index polymers |
US11015023B2 (en) | 2011-08-11 | 2021-05-25 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Fire retardant compositions utilizing elemental sulfur |
US11795248B2 (en) | 2011-08-11 | 2023-10-24 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Copolymerization of elemental sulfur and epoxy functional styrenics |
EP2742084A1 (en) | 2011-08-11 | 2014-06-18 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | High sulfur content copolymers and composite materials and electrochemical cells and optical elements using them |
US9567439B1 (en) | 2011-08-11 | 2017-02-14 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Sulfur composites and polymeric materials from elemental sulfur |
CN104080334A (zh) * | 2011-09-14 | 2014-10-01 | 新天然替代品公司 | 高生物利用度的零价硫的制备和组合物及其用途 |
JP2017517603A (ja) * | 2014-02-14 | 2017-06-29 | ザ アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティー オブ アリゾナThe Arizona Board of Regents on behalf of The University of Arizona | 元素状硫黄に由来する硫黄複合材及び重合体材料 |
US10894863B2 (en) | 2014-02-14 | 2021-01-19 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Cathode materials for Li—S batteries |
US9795676B2 (en) | 2014-03-03 | 2017-10-24 | Shayne Kenneth Morris | Chromium 4-hydroxyisoleucinate compound methods for prepartion and use |
EP3151671A4 (en) * | 2014-06-03 | 2018-03-07 | Sulfagenix, Inc. | Methods and compositions for treating nitric oxide deficiency disorders and related conditions |
JP6806965B2 (ja) * | 2014-07-29 | 2021-01-06 | 国立大学法人 筑波大学 | 精子機能改善剤とこれを含む医薬品組成物、飼料、食品組成物及び家畜または家禽の精子機能改善方法 |
WO2016159612A1 (ko) * | 2015-03-27 | 2016-10-06 | 서울대학교산학협력단 | 폴리설파이드 공중합체 나노입자 및 그의 제조 방법 |
US11078333B2 (en) | 2015-07-13 | 2021-08-03 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Copolymerization of elemental sulfur to synthesize high sulfur content polymeric materials |
US10238685B2 (en) * | 2015-12-02 | 2019-03-26 | Johnson & Johnson Consumer Inc. | Compositions containing polymeric sulfur and uses thereof |
US20170252369A1 (en) * | 2016-03-03 | 2017-09-07 | Frederick J. Sawaya | Method for treating parkinson disease, neurodegenerative disorders, and autoimmune diseases |
CN107281215A (zh) * | 2016-04-01 | 2017-10-24 | 复旦大学附属妇产科医院 | 硫化氢供体硫氢化钠在制药中的用途 |
WO2018107169A1 (en) | 2016-12-09 | 2018-06-14 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Metallopolymers for catalytic generation of hydrogen |
MX2019009384A (es) * | 2017-02-09 | 2019-12-11 | Noxsano Inc | Composiciones generadoras de gastrotransmisores electroquimicos y sus metodos de uso y apositos y sistemas de tratamiento que los incorporan. |
US20180271823A1 (en) * | 2017-03-23 | 2018-09-27 | Washington State University | Sulfur-based broad spectrum antivirals |
US11674005B2 (en) | 2017-06-15 | 2023-06-13 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Chalcogenide Hybrid Inorganic/organic Polymer (CHIP) materials as improved crosslinking agents for vulcanization |
FR3072024A1 (fr) * | 2017-10-11 | 2019-04-12 | Olivier Petitjean | Prevention et traitement de l’hyperplasie benigne de la prostate a l‘aide d’un inhibiteur selectif de la production d’especes reactives de l’oxygene d’origine mitochondriale |
CN108486081B (zh) * | 2018-05-04 | 2021-07-02 | 山西大学 | 一种植物巯基丙酮酸硫转移酶及其应用 |
WO2020046635A1 (en) * | 2018-08-28 | 2020-03-05 | The Regents Of The University Of California | Tetrathionate for cyanide and methylmercaptan poisoning |
BR112022022263A2 (pt) * | 2020-05-04 | 2022-12-20 | Sulfagenix Inc | Tratamento de infecções virais |
FR3125409A1 (fr) * | 2021-07-26 | 2023-01-27 | Nuribiol | Complément alimentaire permettant de lutter contre l’infertilité féminine et masculine |
IT202100021548A1 (it) * | 2021-08-09 | 2023-02-09 | Universita’ Di Pisa | Coniugati della metformina e loro impiego terapeutico |
WO2023079466A2 (en) * | 2021-11-03 | 2023-05-11 | Sulfagenix, Inc. | Treatment of sequelae of coronavirus infections |
EP4212149A1 (en) | 2022-01-18 | 2023-07-19 | Rijksuniversiteit Groningen | Oral dosage forms of acid-labile salt and methods and uses related thereto |
WO2024127426A1 (en) * | 2022-12-12 | 2024-06-20 | Polishetty Ravishankar | An herbal formulation prs-01 for regeneration of the cardiomyocytes |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1213050B (it) * | 1986-03-14 | 1989-12-07 | Schiena Ricerche | Composizioni farmaceutiche topiche in odontostomatologia contenenti allantoina e zolfo elementare |
US5100653A (en) * | 1991-02-08 | 1992-03-31 | Giovanni Campo | Topical compositions for treating mouth tissues |
US6514489B1 (en) | 2000-06-30 | 2003-02-04 | Medicis Pharmaceutical Corp. | Sulfur containing dermatological compositions and methods for reducing malodors in dermatological compositions |
US6855342B2 (en) | 2000-06-30 | 2005-02-15 | Medicis Pharmaceutical Corporation | Compositions and methods for high sorption of skin materials and delivery of sulfur |
AUPS255402A0 (en) * | 2002-05-27 | 2002-06-13 | Monash University | Agents and methods for the treatment of disorders associated with oxidative stress |
US20030235571A1 (en) * | 2002-06-19 | 2003-12-25 | Gabriel Gojon-Romanillos | Systemic treatment of pathological conditions resulting from oxidative stress and/or redox imbalance |
US8361514B2 (en) * | 2002-06-19 | 2013-01-29 | Nuevas Alternatives Naturales Thermafat, S.A.P.I. de C.V. | Systemic treatment of pathological conditions resulting from oxidative stress and/or redox imbalance |
CN1320925C (zh) * | 2005-03-30 | 2007-06-13 | 淮北市辉克药业有限公司 | 长期使用的治疗糖尿病的复方制剂 |
US7741359B2 (en) * | 2005-05-27 | 2010-06-22 | Antibe Therapeutics Inc. | Hydrogen sulfide derivatives of non-steroidal anti-inflammatory drugs |
WO2007140588A1 (en) * | 2006-06-02 | 2007-12-13 | Natural Ma Inc. | Pathogenic attenuation via the administration of an equilibiotic compound |
US7923037B2 (en) | 2006-10-05 | 2011-04-12 | Ikaria, Inc. | Liquid chalcogenide compositions and methods of manufacturing and using the same |
US20120135091A1 (en) * | 2007-01-18 | 2012-05-31 | Roth Mark B | Methods and compositions for enhancing lifespan involving sirtuin-modulating compounds and chalcogenides |
US20080318864A1 (en) * | 2007-06-25 | 2008-12-25 | Fred Hutchinson Cancer Research Center | Methods and compositions regarding polychalcogenide compositions |
EP2167068A2 (en) | 2007-07-05 | 2010-03-31 | Inserm-Institut National De La Sante Et De La Recherche Medicale | Anticonvulsive pharmaceutical compositions |
CN101467991B (zh) * | 2007-08-02 | 2012-02-01 | 复旦大学 | 烯丙基半胱氨酸及其类似物在制备治疗心肌损伤药物中的用途 |
EP2326321A1 (en) | 2008-09-12 | 2011-06-01 | Inserm (Institut National de la Santé et de la Recherche Scientifique) | Taurine or taurine-like substances for the prevention of brain oedema |
RU2406477C1 (ru) | 2009-08-25 | 2010-12-20 | Федеральное государственное учреждение "Научно-исследовательский центр курортологии и реабилитации Федерального агентства по здравоохранению и социальному развитию" (ФГУ "НИЦКиР Росздрава") | Способ лечения ишемической болезни сердца, стенокардии напряжения i-ii функциональных классов |
US8680151B2 (en) | 2010-02-11 | 2014-03-25 | Fred Hutchinson Cancer Research Center | Compounds, compositions and methods for treating or preventing hypoxic or ischemic injury |
US9096504B2 (en) * | 2010-12-01 | 2015-08-04 | Washington State University | Controlled chemical release of hydrogen sulfide |
CN104080334A (zh) * | 2011-09-14 | 2014-10-01 | 新天然替代品公司 | 高生物利用度的零价硫的制备和组合物及其用途 |
-
2012
- 2012-09-13 CN CN201280055604.5A patent/CN104080334A/zh active Pending
- 2012-09-13 AU AU2012308501A patent/AU2012308501A1/en not_active Abandoned
- 2012-09-13 ES ES12840653T patent/ES2739628T3/es active Active
- 2012-09-13 BR BR112014005144-5A patent/BR112014005144B1/pt not_active IP Right Cessation
- 2012-09-13 CA CA2847589A patent/CA2847589C/en active Active
- 2012-09-13 JP JP2014530618A patent/JP5992525B2/ja active Active
- 2012-09-13 JP JP2014530796A patent/JP2014526511A/ja active Pending
- 2012-09-13 WO PCT/MX2012/000086 patent/WO2013055199A1/es active Application Filing
- 2012-09-13 BR BR122020020392-7A patent/BR122020020392B1/pt not_active IP Right Cessation
- 2012-09-13 MX MX2014003288A patent/MX2014003288A/es unknown
- 2012-09-13 EP EP12840653.5A patent/EP2756757B1/en active Active
- 2012-09-13 EP EP12830924.2A patent/EP2755478A4/en not_active Withdrawn
- 2012-09-13 US US14/345,044 patent/US20150064286A1/en not_active Abandoned
- 2012-09-13 AU AU2012321444A patent/AU2012321444B2/en not_active Ceased
- 2012-09-13 BR BR112014004859A patent/BR112014004859A2/pt unknown
- 2012-09-13 US US13/614,820 patent/US8771755B2/en active Active
- 2012-09-13 CA CA2847264A patent/CA2847264A1/en not_active Abandoned
- 2012-09-13 MX MX2014003289A patent/MX360050B/es active IP Right Grant
- 2012-09-13 WO PCT/US2012/055205 patent/WO2013040240A1/en active Application Filing
- 2012-09-13 CN CN201280055643.5A patent/CN104080339B/zh not_active Expired - Fee Related
-
2014
- 2014-04-16 US US14/254,396 patent/US20140322361A1/en not_active Abandoned
-
2015
- 2015-01-23 HK HK15100731.7A patent/HK1200277A1/xx unknown
- 2015-01-23 HK HK15100737.1A patent/HK1200278A1/xx unknown
- 2015-08-06 AU AU2015210403A patent/AU2015210403B2/en not_active Ceased
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112014004859A2 (pt) | preparação e composições de enxofre zerovalente altamente biodisponíveis e usos das mesmas | |
UY35472A (es) | Compuestos y sus usos en la modulacion de la hemoglobina | |
BR112015022998A2 (pt) | composições melhoradas para o tratamento de distrofia muscular | |
ECSP14017269A (es) | Compuestos para tratar la atrofia muscular espinal | |
DOP2014000233A (es) | Compuestos de microarn y métodos de modulación de la actividad de mir-21 | |
CL2014002077A1 (es) | Composicion farmaceutica que comprende fumarato de dimetilo; metodo de preparacion; capsula que comprende microtabletas de fumarato de dimetilo; metodo para el tratamiento, profilaxis o mejora de la esclerosis multiple. | |
IN2014DN09782A (pt) | ||
BR112012025558A2 (pt) | tratamento para a ataxia-telangiectasia | |
BR112013026032A2 (pt) | composições nutricionais incluindo ácidos graxos de cadeia ramificada para cicatrização de ferida | |
BR112014026703A2 (pt) | inibidores de dna-pk | |
MX2014008705A (es) | Compuestos tricíclicos de sulfona y métodos para elaborarlos y utilizarlos. | |
BR112015000150A2 (pt) | composições farmacêuticas dissuasoras de abuso de liberação controlada | |
BR112014027571A2 (pt) | métodos para o tratamento de retinopatia diabética e outras doenças oftalmológicas | |
BR112012027915A2 (pt) | nitro-ácidos graxos - neuroproteção e/ou inibição do declínio cognitivo | |
BR112016027871A2 (pt) | composição para melhorar a memória, a função de aprendizado e/ou função cognitiva | |
MX2012013731A (es) | Vacunas que comprenden colesterol y cpg como moleculas portadoras-adyuvantes unicas. | |
FR2969495B1 (fr) | Extrait de parties aeriennes de maca riche en polyphenols et composition le comprenant | |
BR112013029256A2 (pt) | "combinações farmacêuticas para uso no tratamento de pacientes com diabetes tipo 2, método de tratamento, e usos de lixisenatida e metformina". | |
BR112015003729A2 (pt) | composto de fórmula estrutural i; composição farmacêutica; método de tratamento de uma doença mediada por caminho do hif; método de tratamento de uma doença causada por proliferação anormal de células; e método para alcançar um efeito em um paciente | |
BR112013001301A2 (pt) | processo para preparar uma composição líquida farmacêutica compreendendo imunoglobulina g humana e composição líquida farmacêutica contendo imunoglobulina g humana | |
UY32937A (es) | Compuestos y composiciones como moduladores de la actividad de gpr119 | |
BR112015013349A2 (pt) | trieptanoína para o tratamento de deficiência de transportador de glicose 1 | |
BR112015004465A2 (pt) | sistemas, dispositivos e métodos para fornecer terapia com orientação de imagem | |
BR112014010376A2 (pt) | medicamento para o tratamento de doença do olho anterior que compreende rebamipida e um agente de retenção de lágrima | |
BR112014019399A2 (pt) | métodos de tratamento da fibrose |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08H | Application fees: decision cancelled [chapter 8.8 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |